The women’s health market is predicted to be among the fastest growing investment areas within the healthcare and life sciences industry. Life sciences companies and healthcare providers, as well as the governmental bodies that regulate them, are abandoning a “one-size-fits-all” approach to treatment in favor of approaches more tailored to specific groups, including women. King & Spalding’s Women’s Health team has decades of experience advising companies in this space on issues that arise throughout the lifecycle of medical products – including intellectual property issues, corporate and M&A issues, FDA-related issues, issues related to product coverage and reimbursement, healthcare provider issues, and product liability issues. Clients include drug and device manufacturers, health care providers, private equity firms, and others.
February 19, 2019
Johnson & Johnson Wins Full Dismissal on the Eve of Trial